Towards patient‐specific tumor antigen selection for vaccination

Summary: In this review, we discuss the possibilities for combining the power of molecular analysis of the antigens expressed in a given individual tumor with the design of a tailored vaccine containing defined antigens. Step 1 is a differential gene expression analysis of tumor and corresponding normal tissue. Step 2 is the analysis of human leukocyte antigen (HLA) ligands on tumor cells. Step 3 is data mining with the aim to select those antigens that might be suitable for tumor attack by the adaptive immune system. Step 4 is the on‐the‐spot clinical grade production of the constituents of the patient tailored vaccine, e.g. peptides. Step 5 is then vaccination and monitoring. Although it will not be possible to cover all relevant antigens expressed in a tumor, the antigens that can be identified with our present technical possibilities might be enough for improved immunotherapy. The scope of the present review is to explore the possibilities and the formidable technical and logistical challenge for such individual patient‐oriented antigen definition to be used for therapeutic immunization.

[1]  D. Jäger,et al.  Clinical cancer vaccine trials. , 2002, Current opinion in immunology.

[2]  Gerd Ritter,et al.  Identification of cancer/testis genes by database mining and mRNA expression analysis , 2002, International journal of cancer.

[3]  Rudolf M. Huber,et al.  Combined transcriptome and genome analysis of single micrometastatic cells , 2002, Nature Biotechnology.

[4]  T. Braun,et al.  A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[5]  J. Karbach,et al.  Peptide‐specific CD8+ T‐cell evolution in vivo: Response to peptide vaccination with Melan‐A/MART‐1 , 2002, International journal of cancer.

[6]  K. Lillemoe,et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.

[7]  M. Bonneville,et al.  Combination of MHC-peptide multimer-based T cell sorting with the Immunoscope permits sensitive ex vivo quantitation and follow-up of human CD8+ T cell immune responses. , 2002, Journal of immunological methods.

[8]  A. Hildesheim,et al.  Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. , 2002, Journal of immunological methods.

[9]  D. Speiser,et al.  In vivo activation of melanoma‐specific CD8+ T cells by endogenous tumor antigen and peptide vaccines. A comparison to virus‐specific T cells , 2002, European journal of immunology.

[10]  B. Leyland-Jones.  Trastuzumab: hopes and realities. , 2002, The Lancet. Oncology.

[11]  W. Schmidt,et al.  Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: induction of potent and long-lasting T-cell responses against cancer antigens. , 2002, Cancer research.

[12]  Odile Burlet-Schiltz,et al.  The Production of a New MAGE-3 Peptide Presented to Cytolytic T Lymphocytes by HLA-B40 Requires the Immunoproteasome , 2002, The Journal of experimental medicine.

[13]  Danila Valmori,et al.  Proteasome-Assisted Identification of a SSX-2-Derived Epitope Recognized by Tumor-Reactive CTL Infiltrating Metastatic Melanoma1 , 2002, The Journal of Immunology.

[14]  D. Speiser,et al.  CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide , 2002, The Journal of Immunology.

[15]  F. Tureček.  Mass spectrometry in coupling with affinity capture-release and isotope-coded affinity tags for quantitative protein analysis. , 2002, Journal of mass spectrometry : JMS.

[16]  T. Wölfel,et al.  The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays. , 2002, Journal of immunological methods.

[17]  J. Remacle,et al.  DNA microarray to monitor the expression of MAGE-A genes. , 2002, Clinical chemistry.

[18]  V. Brusic,et al.  NY-ESO-1 119-143 is a promiscuous major histocompatibility complex class II T-helper epitope recognized by Th1- and Th2-type tumor-reactive CD4+ T cells. , 2002, Cancer research.

[19]  Peter M. Haverty,et al.  HugeIndex: a database with visualization tools for high-density oligonucleotide array data from normal human tissues , 2002, Nucleic Acids Res..

[20]  Alex E. Lash,et al.  Gene Expression Omnibus: NCBI gene expression and hybridization array data repository , 2002, Nucleic Acids Res..

[21]  C. Creaser,et al.  Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. , 2001, Blood.

[22]  S. Stevanović,et al.  Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens. , 2001, Journal of immunological methods.

[23]  M Vingron,et al.  Identification and Classification of Differentially Expressed Genes in Renal Cell Carcinoma by Expression Profiling on a Global Human 31 , 500-Element cDNA Array , 2001 .

[24]  J. Nesland,et al.  Frameshift-mutation-derived peptides as tumor-specific antigens in inherited and spontaneous colorectal cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  F. Naour.  Contribution of proteomics to tumor immunology , 2001 .

[26]  V. Engelhard,et al.  Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  S M Hanash,et al.  Protein based microarrays: A tool for probing the proteome of cancer cells and tissues , 2001, Proteomics.

[28]  P. Coulie,et al.  A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3 , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  K. Furge,et al.  Gene expression profiling of clear cell renal cell carcinoma: Gene identification and prognostic classification , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[30]  H. Rammensee,et al.  Discrete Cleavage Motifs of Constitutive and Immunoproteasomes Revealed by Quantitative Analysis of Cleavage Products , 2001, The Journal of experimental medicine.

[31]  Yan P. Yuan,et al.  Frameshift peptide‐derived T‐cell epitopes: A source of novel tumor‐specific antigens , 2001, International journal of cancer.

[32]  D. Speiser,et al.  Ex Vivo IFN-γ Secretion by Circulating CD8 T Lymphocytes: Implications of a Novel Approach for T Cell Monitoring in Infectious and Malignant Diseases1 , 2001, The Journal of Immunology.

[33]  Jonathan W. Yewdell,et al.  Immunoproteasomes Shape Immunodominance Hierarchies of Antiviral Cd8+ T Cells at the Levels of T Cell Repertoire and Presentation of Viral Antigens , 2001, The Journal of experimental medicine.

[34]  V. Engelhard,et al.  Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients , 2001, International journal of cancer.

[35]  I. Saeterdal,et al.  Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM‐CSF as adjuvant , 2001, Experimental dermatology.

[36]  Steven A. Rosenberg,et al.  Progress in human tumour immunology and immunotherapy , 2001, Nature.

[37]  B. Gückel,et al.  A MAGE-A1 HLA-A A*0201 epitope identified by mass spectrometry. , 2001, Cancer research.

[38]  F. Marshall,et al.  Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. , 2001, The American journal of pathology.

[39]  M. Pfreundschuh,et al.  Clinical approaches to vaccination in oncology , 2001, Annals of Hematology.

[40]  L. Loeb,et al.  A mutator phenotype in cancer. , 2001, Cancer research.

[41]  D. Cahill,et al.  Protein and antibody arrays and their medical applications. , 2001, Journal of immunological methods.

[42]  J. Yewdell,et al.  At the crossroads of cell biology and immunology: DRiPs and other sources of peptide ligands for MHC class I molecules. , 2001, Journal of cell science.

[43]  P. Robbins,et al.  A listing of human tumor antigens recognized by T cells , 2001, Cancer Immunology, Immunotherapy.

[44]  K. Hadeler,et al.  PAProC: a prediction algorithm for proteasomal cleavages available on the WWW , 2001, Immunogenetics.

[45]  R. Offringa,et al.  The self peptide annexin II (208–223) presented by dendritic cells sensitizes autologous CD4+ T lymphocytes to recognize melanoma cells , 2001, Cancer Immunology, Immunotherapy.

[46]  Ferry Ossendorp,et al.  Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis , 2001, The Journal of experimental medicine.

[47]  Donna R. Maglott,et al.  RefSeq and LocusLink: NCBI gene-centered resources , 2001, Nucleic Acids Res..

[48]  J. Dillner,et al.  Immunity to oncogenic human papillomaviruses. , 2001, Advances in cancer research.

[49]  A. Harris,et al.  A Shift in the Phenotype of Melan-A-Specific CTL Identifies Melanoma Patients with an Active Tumor-Specific Immune Response1 , 2000, The Journal of Immunology.

[50]  S. Steinberg,et al.  The use of a rapid ELISPOT assay to analyze peptide-specific immune responses in carcinoma patients to peptide vs. recombinant poxvirus vaccines , 2000, Cancer Immunology, Immunotherapy.

[51]  J. Bristol,et al.  Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization. , 2000, Cellular immunology.

[52]  L. Kanz,et al.  Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. , 2000, Blood.

[53]  D. Jäger,et al.  Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[54]  A. Eggermont,et al.  Quantitation of antigen-reactive T cells in peripheral blood by IFNgamma-ELISPOT assay and chromium-release assay: a four-centre comparative trial. , 2000, Journal of immunological methods.

[55]  T. Schumacher,et al.  In situ detection of virus- and tumor-specific T-cell immunity , 2000, Nature Medicine.

[56]  H. Rammensee,et al.  Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. , 2000, Cancer research.

[57]  W. Schultze‐Seemann,et al.  Enhanced expression of IFN- γ mRNA in CD4+or CD8+tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer , 2000, British Journal of Cancer.

[58]  S. Altschul,et al.  SAGEmap: a public gene expression resource. , 2000, Genome research.

[59]  Cécile Gouttefangeas,et al.  Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.

[60]  D. Jäger,et al.  Clonal expansion of melan a‐specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma‐associated peptides , 2000, International journal of cancer.

[61]  M. Ashburner,et al.  Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.

[62]  J. Neefjes,et al.  The major substrates for TAP in vivo are derived from newly synthesized proteins , 2000, Nature.

[63]  Hans-Georg Rammensee,et al.  Perfect use of imperfection , 2000, Nature.

[64]  D. McNeel,et al.  Delayed-type hypersensitivity response is a predictor of peripheral blood T-cell immunity after HER-2/neu peptide immunization. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  R. Zinkernagel,et al.  Immunotherapy with Dendritic Cells Directed against Tumor Antigens Shared with Normal Host Cells Results in Severe Autoimmune Disease , 2000, The Journal of experimental medicine.

[66]  M. Probst-Kepper,et al.  Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells. , 2000, Immunity.

[67]  M. Probst-Kepper,et al.  A New Antigen Recognized by Cytolytic T Lymphocytes on a Human Kidney Tumor Results from Reverse Strand Transcription , 1999, The Journal of experimental medicine.

[68]  E. Wang,et al.  Functional analysis of antigen-specific T lymphocytes by serial measurement of gene expression in peripheral blood mononuclear cells and tumor specimens. , 1999, Journal of immunology.

[69]  S. Stevanović,et al.  Quantitative aspects of T cell activation--peptide generation and editing by MHC class I molecules. , 1999, Seminars in immunology.

[70]  Ash A. Alizadeh,et al.  Genome-wide analysis of DNA copy number variation in breast cancer using DNA microarrays , 1999, Nature Genetics.

[71]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[72]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[73]  H. Rammensee,et al.  Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. , 1999, Blood.

[74]  Mario Roederer,et al.  Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients , 1999, Nature Medicine.

[75]  H. Ertl,et al.  Immune responses to DNA vaccines , 1999, Cellular and Molecular Life Sciences CMLS.

[76]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[77]  S. Rowland-Jones,et al.  A re-evaluation of the frequency of CD8+ T cells specific for EBV in healthy virus carriers. , 1999, Journal of immunology.

[78]  P. Coulie,et al.  Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE‐3 and presented by HLA‐A1 , 1999, International journal of cancer.

[79]  G. Ogg,et al.  Ex Vivo Staining of Metastatic Lymph Nodes by Class I Major Histocompatibility Complex Tetramers Reveals High Numbers of Antigen-experienced Tumor-specific Cytolytic T Lymphocytes , 1998, The Journal of experimental medicine.

[80]  M. Lotze,et al.  Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. , 1998, Journal of immunology.

[81]  E. Gilboa,et al.  Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA , 1998, Nature Biotechnology.

[82]  G. Ogg,et al.  Direct isolation, phenotyping and cloning of low-frequency antigen-specific cytotoxic T lymphocytes from peripheral blood , 1998, Current Biology.

[83]  Dirk Schadendorf,et al.  Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.

[84]  D. Jäger,et al.  Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes , 1998, The Journal of experimental medicine.

[85]  A. Lanzavecchia,et al.  The duration of antigenic stimulation determines the fate of naive and effector T cells. , 1998, Immunity.

[86]  V. Apostolopoulos,et al.  Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. , 1997, The Journal of clinical investigation.

[87]  H. Seigler,et al.  A phase I clinical trial of immunotherapy with interferon‐γ gene‐modified autologous melanoma cells , 1997 .

[88]  M. Pfreundschuh,et al.  Serological analysis of human tumor antigens: molecular definition and implications. , 1997, Molecular medicine today.

[89]  K. Mechtler,et al.  Cell-free tumor antigen peptide-based cancer vaccines. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[90]  M. Theobald,et al.  Tolerance to p53 by A2.1-restricted Cytotoxic T Lymphocytes , 1997, The Journal of experimental medicine.

[91]  Philip J. R. Goulder,et al.  Phenotypic Analysis of Antigen-Specific T Lymphocytes , 1996, Science.

[92]  J. Yewdell,et al.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.

[93]  F. Oesch,et al.  Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic‐T‐cell responses: Evidence for immunoselection of antigen‐loss variants in vivo , 1996, International journal of cancer.

[94]  G. Gaudernack.  T cell responses against mutant ras: a basis for novel cancer vaccines. , 1996, Immunotechnology : an international journal of immunological engineering.

[95]  J. Schlom,et al.  Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses , 1996, European journal of immunology.

[96]  J. Shabanowitz,et al.  An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins , 1996, The Journal of experimental medicine.

[97]  M. Pfreundschuh,et al.  Human neoplasms elicit multiple specific immune responses in the autologous host. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Ronald W. Davis,et al.  Quantitative Monitoring of Gene Expression Patterns with a Complementary DNA Microarray , 1995, Science.

[99]  K. Kinzler,et al.  Serial Analysis of Gene Expression , 1995, Science.

[100]  D. Byrd,et al.  Antibody to ras proteins in patients with colon cancer. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[101]  M. Serrano,et al.  A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma , 1995, Science.

[102]  J. Schlom,et al.  Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine. , 1995, Journal of the National Cancer Institute.

[103]  M. Esteban,et al.  Quantification of antigen specific CD8+ T cells using an ELISPOT assay. , 1995, Journal of immunological methods.

[104]  R. Henderson,et al.  Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. , 1994, Science.

[105]  H. Grey,et al.  Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[106]  S. Stacey,et al.  Human cytotoxic T lymphocytes stimulated by endogenously processed human papillomavirus type 11 E7 recognize a peptide containing a HLA-A2 (A*0201) motif. , 1994, Immunology.

[107]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[108]  Wei Chen,et al.  Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.

[109]  R. Brandt,et al.  Strict peptide length is not required for the induction of cytotoxic T lymphocyte‐mediated antiviral protection by peptide vaccination , 1993, European journal of immunology.

[110]  E. Thorsby,et al.  Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln-->Leu61). , 1992, International immunology.

[111]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[112]  R. Henderson,et al.  Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry. , 1992, Science.

[113]  P. Coulie,et al.  Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells , 1992, International journal of cancer.

[114]  P. Chomez,et al.  A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. , 1991, Science.

[115]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.

[116]  S. Nathenson,et al.  Isolation of an endogenously processed immunodominant viral peptide from the class I H–2Kb molecule , 1990, Nature.

[117]  P. Chomez,et al.  Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[118]  D. Cheresh,et al.  Disialoganglioside GD3 on human melanoma serves as a relevant target antigen for monoclonal antibody-mediated tumor cytolysis. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[119]  D. Pim,et al.  Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer , 1982, International journal of cancer.

[120]  J. Mach,et al.  Antibody-dependent cell-mediated cytolysis of human colon carcinoma cells induced by specific antisera against carcinoembryonic antigen. , 1977, Cancer research.